GSK PLC SP. ADR/2 NEW - Asset Resilience Ratio
GSK PLC SP. ADR/2 NEW (GS70) has an Asset Resilience Ratio of 0.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore GSK PLC SP. ADR/2 NEW asset portfolio for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how GSK PLC SP. ADR/2 NEW's Asset Resilience Ratio has changed over time. See debt-free asset ratio of GSK PLC SP. ADR/2 NEW to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down GSK PLC SP. ADR/2 NEW's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GSK PLC SP. ADR/2 NEW market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.00 Million | 0.0% |
| Total Liquid Assets | €1.00 Million | 0.00% |
Asset Resilience Insights
- Limited Liquidity: GSK PLC SP. ADR/2 NEW maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
GSK PLC SP. ADR/2 NEW Industry Peers by Asset Resilience Ratio
Compare GSK PLC SP. ADR/2 NEW's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.03% |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357 |
Drug Manufacturers - General | 9.91% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
Annual Asset Resilience Ratio for GSK PLC SP. ADR/2 NEW (2021–2025)
The table below shows the annual Asset Resilience Ratio data for GSK PLC SP. ADR/2 NEW.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | €9.00 Million ≈ $10.52 Million |
€61.12 Billion ≈ $71.45 Billion |
-0.02pp |
| 2024-12-31 | 0.04% | €21.00 Million ≈ $24.55 Million |
€59.46 Billion ≈ $69.52 Billion |
-3.77pp |
| 2023-12-31 | 3.81% | €2.25 Billion ≈ $2.63 Billion |
€59.01 Billion ≈ $68.98 Billion |
-3.10pp |
| 2022-12-31 | 6.91% | €4.15 Billion ≈ $4.86 Billion |
€60.15 Billion ≈ $70.32 Billion |
+6.83pp |
| 2021-12-31 | 0.08% | €61.00 Million ≈ $71.32 Million |
€79.10 Billion ≈ $92.48 Billion |
-- |
About GSK PLC SP. ADR/2 NEW
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more